Six Upgrades to Guarantee L4 Self-Driving Operation! RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus
RoboSense , a world-leading provider of Smart LiDAR Sensor Systems launched upgraded 128-beam LiDAR, RS-Ruby Plus , designed for autonomous driving commercial operation, and it debuted at CES2022. Nowadays, it obtained a large number of orders from multiple autonomous vehicle companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005763/en/
RS-Ruby Plus (Photo: Business Wire)
Breaking through the limitations of the previous generation RS-Ruby，the RS-Ruby Plus adopts a new modular architecture design, which reduces its size and weight by 50% compared with the previous generation, and reduces power consumption to 30W, which is 33% lower than RS-Ruby. In the past two years, RS-Ruby has supported Momenta, IdriverPlus, DeepRoute.ai, AutoX, Mushroom Car Alliance and over thousands RoboTaxi fleets in pilot commercial operations with its stable and reliable operation performance.
Six Upgrades of RS-Ruby Plus：
1. Automotive-grade design for reliability as the reference
RoboSense developed a new architecture design for RS-Ruby Plus with reference to automotive-grade standards to ensure that the product passes tens of automotive-grade reliability tests including mechanical shock, random vibration, low temperature operation, high-pressure water impact and EMC.
Watch：RS-Ruby Plus passed dozens of reliability tests
2. Comprehensively improve the perception distance
RoboSense achieved a breakthrough in the detection range of 905nm LiDAR on the premise of ensured safety of human eyes. The product reached a super detection range of 240m @10% standard reflectivity (under 100,000 Lux sunlight environment) and the overall detection range performance improved by 20%.
In the high-performance mode, Ruby Plus can increase the horizontal angular resolution of 128 channels from 0.2° to 0.1° at 10Hz refresh rate, thus providing more point cloud information in the horizontal direction. Meanwhile, 104 channels 0.1° vertical resolution, including 32 channels ultra-long detection range. RS-Ruby Plus detects cars at 218 meters with 4 lines and 13 points.
Watch：RS-Ruby Plus point cloud in various scenarios
3. Detection capability of black-painted vehicles boosted
Empowered by the super detection range capability, RS-Ruby Plus greatly improving the detection and recognition capabilities of perception for black vehicles.
The road line detection capability of RS-Ruby Plus has been improved, it stably detects 85-90 meters, thus further improving the safety and user experience of autonomous vehicles when changing lanes and going up and down ramps.
4. Higher accuracy and finer imaging
Detection range accuracy improvement of RS-Ruby Plus
- Near-field area 0.4~3m, accuracy up to ±3cm (@100,000 Lux lighting environment)
- Far-field area 3~240m, accuracy up to ±2cm (@100,000 Lux lighting environment)
The higher accuracy of LiDAR, the more precise and clear the shape of small objects like stone piers, lampposts and traffic cones can be restored.
5. Comprehensive anti-interference
RS-Ruby Plus uses the latest laser encryption technology, RS-Ruby Plus effectively resists interference from other LiDARs and ambient light and sunlight (100,000 Lux lighting).
6. Automotive Ethernet, gPTP, PTP
RS-Ruby Plus has automotive Ethernet interface. The product supports both GPS synchronization and network synchronization (PTP and gPTP time synchronization) protocols, which greatly reduces data transmission delay and simplifies cable layout.
RoboSense will always employ more advanced technology innovations and feature ever superior performance to empower industry partners, support the comprehensive commercialization of autonomous driving.
Read More: RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005763/en/
Contact information
Grace Ye
Media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom